Antithrombin III for critically ill patients

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Antithrombin III for critically ill patients. / Afshari, Arash; Wetterslev, Jørn; Brok, Jesper Sune; Møller, Ann Merete.

In: Cochrane Database of Systematic Reviews, No. 3, 01.01.2008, p. CD005370.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Afshari, A, Wetterslev, J, Brok, JS & Møller, AM 2008, 'Antithrombin III for critically ill patients', Cochrane Database of Systematic Reviews, no. 3, pp. CD005370. https://doi.org/10.1002/14651858.CD005370.pub2, https://doi.org/10.1002/14651858.CD005370.pub2

APA

Afshari, A., Wetterslev, J., Brok, J. S., & Møller, A. M. (2008). Antithrombin III for critically ill patients. Cochrane Database of Systematic Reviews, (3), CD005370. https://doi.org/10.1002/14651858.CD005370.pub2, https://doi.org/10.1002/14651858.CD005370.pub2

Vancouver

Afshari A, Wetterslev J, Brok JS, Møller AM. Antithrombin III for critically ill patients. Cochrane Database of Systematic Reviews. 2008 Jan 1;(3):CD005370. https://doi.org/10.1002/14651858.CD005370.pub2, https://doi.org/10.1002/14651858.CD005370.pub2

Author

Afshari, Arash ; Wetterslev, Jørn ; Brok, Jesper Sune ; Møller, Ann Merete. / Antithrombin III for critically ill patients. In: Cochrane Database of Systematic Reviews. 2008 ; No. 3. pp. CD005370.

Bibtex

@article{59a60830f75f11ddbf70000ea68e967b,
title = "Antithrombin III for critically ill patients",
abstract = "Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties but the efficacy and any harmful effects of AT III supplementation in critically ill patients are unknown.",
author = "Arash Afshari and J{\o}rn Wetterslev and Brok, {Jesper Sune} and M{\o}ller, {Ann Merete}",
note = "Times Cited: 0ReviewEnglishAfshari, AUniv Copenhagen, Rigshosp, Dept Paediat & Obstet Anaesthesiol, Blegdamsvej 9, DK-2100 Copenhagen O, DenmarkCited References Count: 87328PSJOHN WILEY & SONS LTDTHE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLANDCHICHESTER",
year = "2008",
month = jan,
day = "1",
doi = "10.1002/14651858.CD005370.pub2",
language = "English",
pages = "CD005370",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "Wiley",
number = "3",

}

RIS

TY - JOUR

T1 - Antithrombin III for critically ill patients

AU - Afshari, Arash

AU - Wetterslev, Jørn

AU - Brok, Jesper Sune

AU - Møller, Ann Merete

N1 - Times Cited: 0ReviewEnglishAfshari, AUniv Copenhagen, Rigshosp, Dept Paediat & Obstet Anaesthesiol, Blegdamsvej 9, DK-2100 Copenhagen O, DenmarkCited References Count: 87328PSJOHN WILEY & SONS LTDTHE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLANDCHICHESTER

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties but the efficacy and any harmful effects of AT III supplementation in critically ill patients are unknown.

AB - Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties but the efficacy and any harmful effects of AT III supplementation in critically ill patients are unknown.

U2 - 10.1002/14651858.CD005370.pub2

DO - 10.1002/14651858.CD005370.pub2

M3 - Journal article

C2 - 18646125

SP - CD005370

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 3

ER -

ID: 10245834